We will contact you within two business days
CAR T-cell therapy at MD Anderson
MD Anderson’s CARTOX Program, which oversees care for the hospital’s CAR T-cell therapy patients, is the first stand-alone immune effector cellular therapy program to earn accreditation from the Foundation for the Accreditation of Cellular Therapy.
Chimeric Antigen Receptor (CAR) T-cell therapy is a type of immunotherapy that changes a patient’s own T cells so they are able to recognize and attack cancer.
After years of clinical trials, in 2017 the Food and Drug Administration approved the use of two CAR T-cell therapies.
Kymriah is for pediatric and young adult patients age 25 or younger with B-cell acute lymphoblastic leukemia. It has also been approved for adult patients with certain types of large B-cell non-Hodgkin lymphoma who have relapsed on not responded to standard treatments.
Yescarta has been approved for patients with large B-cell non-Hodgkin lymphoma that has relapsed or does not respond to standard treatments.